$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Meta Expands AI Training With Employee Activity Tracking Tools 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
PHILADELPHIA, March 02, 2016 -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that Jeffrey D. Marrazzo, co-founder and chief executive officer, is presenting at the Cowen 36th Annual Health Care Conference on Monday, March 7, 2016 at 4:40 pm (EST), at the Marriott Copley Place, Boston, Massachusetts.
To access the slide deck presented, please visit the "Investor Presentations" section of the Spark Therapeutics website at www.sparktx.com.
About Spark Therapeutics
Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark’s most advanced product candidate, SPK-RPE65 (voretigene neparvovec), which has received both breakthrough therapy and orphan product designation, recently reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark builds on two decades of research, development and manufacturing at The Children’s Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com.
Contacts Investor Relations Spark Therapeutics, Inc. Stephen W. Webster Chief Financial Officer (855) SPARKTX (1-855-772-7589) Media Ten Bridge Communications Dan Quinn (781) 475-7974 [email protected]
